Viking Holdings Ltd Ordinary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Viking Holdings Ltd Ordinary Shares trades at $81.39 (market cap $36.46B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Viking Holdings Ltd Ordinary Shares is far larger — about 3.6× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Viking Holdings Ltd Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Viking Holdings Ltd Ordinary Shares for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VIK | XBI | |
|---|---|---|
Market Cap | $36.46B | $10.11B |
Volume | 3,461,906 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $108.26 | $169.55 |
52-Week Low | $57.08 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $38.84B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Viking operates river, ocean, and expedition cruises. Its itineraries focus on destination-based travel across Europe, the Americas, and other regions.
Read more on VIK →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →